Tempting treat or hidden trigger? The surprising impact of chocolate on your digestion
Chocolate, a beloved indulgence for many, could have unexpected consequences on your health, particularly when it comes to your digestive system. While it’s known for its relaxing effects and mood-boosting abilities, chocolate, especially dark chocolate high in cocoa, can negatively impact the function of your esophagus.
In an exclusive interview with DC Medical and DC News’ Health Academy, Professor Emeritus Silviu Constantinoiu, a specialist in esophageal surgery, explains how chocolate consumption can exacerbate gastroesophageal reflux (GERD) and offers solutions for those who refuse to forgo this culinary delight.
"During a manometry test, the normal pressure of the lower esophageal sphincter (LES) is roughly between 12 and 20 millimeters of mercury. When the pressure drops below 10, often below 8, reflux appears. Chocolate, particularly dark chocolate which contains cocoa, can decrease this pressure," Professor Constantinoiu reveals.
He suggests, "If one still enjoys chocolate, they might consider switching to white chocolate, which is cocoa-free."
Chocolate can be a common trigger for GERD, and individuals experiencing heartburn or reflux should consider safer alternatives to protect their esophageal health. Opting for white chocolate could be a solution, but as always, consulting a specialist remains crucial for adequate dietary management and digestive health.
Chocolate’s acid reflux-inducing potential stems from several reasons. Its high fat and caffeine content can relax the LES muscle, allowing stomach acid to flow into the esophagus. Additionally, chocolate contains theobromine, which stimulates gastric acid production. Moreover, sugar and other additives in chocolate can contribute to esophageal mucosal inflammation, worsening acid reflux symptoms.
Learn more in this video:
[embedded video link]
Stay informed with the latest news. Follow DC Medical and on Google News to keep up with the newest developments.
Did this article help you?
Follow DC Medical on Facebook and Instagram for more useful content on health, disease prevention, treatment, first aid tips, and helpful insights from doctors and patients.
- Social Media Driving Misuse of Alzheimer’s Blood Tests
- Dengue-Carrying Mosquitoes Expand Into Florida and New Territories
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)